Log In Sign up
The largest database of trusted experimental protocols

Anti cd19 violet421

Manufactured by BioLegend
Visit Supplier

Anti-CD19-Violet421 is a monoclonal antibody that binds to the CD19 antigen. It is conjugated to the Violet421 fluorescent dye.

Automatically generated - may contain errors

Lab products found in correlation

Anti f4 80 fitc, by Thermo Fisher Scientific (2 mentions) Anti cd8 pe cy7, by BioLegend (2 mentions) Anti nk1.1 pe cy7, by Thermo Fisher Scientific (2 mentions) Anti b220 percp, by BioLegend (2 mentions) Anti cd3 e450, by Thermo Fisher Scientific (2 mentions) Anti cd11c violet 421, by BioLegend (2 mentions) Anti mhcii percp, by BioLegend (2 mentions)

Spelling variants of this product

Anti-CD19 (91 citations) CD19-Violet421 (2 citations)

2 protocols using anti cd19 violet421

1

Multiparametric Immune Profiling of Murine Bone Marrow

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated bone marrow cells from 3 month old mice and were blocked for non-specific staining in 2% BSA and with anti-CD16 (5 µg/mL) for 20′ at 4°C. Afterwards, cells were stained in 2% BSA with anti-CD4-Violet421 (1:100, Pharminogen), anti-CD8-PE-Cy7 (1:100, Biolegend), anti-F4/80- Fitc (1:100, eBiosciences), anti-CD3-e450 (eBiosciences), anti-NK1.1- PE-Cy7 (eBiosciences), anti-CD19-Violet421 (1:100, Biolegend) and anti-B220-PerCP (1:100, Biolegend), anti-CD11c-Violet 421 (1:100, Biolegend), anti-MHCII-PerCP (1:100, Biolegend). At last, the cells were washed twice in 2% BSA and analyzed by flow cytometry using Attune (Invitrogen), and FlowJo.
Dibra D., Mitra A., Xia X., Newman M., Cutrera J., Gagea M., Kleinerman E., Lozano G, & Li S. (2016). Lack of immunomodulatory Interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(15), 3876-3883.
+ Open protocol
+ Expand
2

Comprehensive Immune Cell Profiling of Murine Bone Marrow

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isolated bone marrow cells from 3 month old mice and were blocked for non-specific staining in 2% BSA and with anti-CD16 (5 μ g/mL) for 20′ at 4°C. Afterwards, cells were stained in 2% BSA with anti-CD4-Violet421 (1:100, Pharminogen), anti-CD8-PE-Cy7 (1:100, Biolegend), anti-F4/80- Fitc (1:100, eBiosciences), anti-CD3-e450 (eBiosciences), anti-NK1.1- PE-Cy7 (eBiosciences), anti-CD19-Violet421 (1:100, Biolegend) and anti-B220-PerCP (1:100, Biolegend), anti-CD11c-Violet 421 (1:100, Biolegend), anti-MHCII-PerCP (1:100, Biolegend). At last, the cells were washed twice in 2% BSA and analyzed by flow cytometry using Attune (Invitrogen), and FlowJo.
Dibra D., Mitra A., Newman M., Xia X., Keenan C., Cutrera J.J., Mathis J.M., Wang X.J., Myers J, & Li S. (2016). IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. Oncotarget, 7(47), 77138-77151.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!